Blueshift Selected by RCS MediaGroup to Revolutionize Multi-Channel Customer Engagement
September 24, 2024 03:01 ET
|
Blueshift Labs, Inc.
London, United Kingdom, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Blueshift, the leading force in intelligent customer engagement, is thrilled to announce an exciting new partnership with RCS...
Utility Solar Tracker Market to reach $34.6 Bn by 2032, Says Global Market Insights Inc.
September 24, 2024 03:00 ET
|
Global Market Insights Inc.
Selbyville, Delaware,, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The utility solar tracker market is projected to hit USD 34.6 billion by 2032, as reported in a research study by Global Market Insights...
Form 8.5 (EPT/RI) - Trinity Exploration & Production Plc
September 24, 2024 02:48 ET
|
Shore Capital Stockbrokers Limited
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) ...
Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis
September 24, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an...
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
September 24, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024 01:00 ET
|
Biogen Inc.
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...
Santhera gibt Annahme des Zulassungsantrags für AGAMREE® (Vamorolon) bei Duchenne-Muskeldystrophie durch Swissmedic bekannt
September 24, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, 24. September 2024 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Schweizerische Heilmittelinstitut Swissmedic das Zulassungsgesuch (marketing authorization...
Duolingo Introduces AI-Powered Innovations at Duocon 2024
September 24, 2024 00:01 ET
|
Duolingo, Inc.
PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Duolingo (NASDAQ:DUOL), the world’s leading mobile learning platform, today announces significant product innovations at its annual conference, Duocon...
BioVie Inc. Announces Pricing of Public Offering
September 23, 2024 22:26 ET
|
BioVie, Inc.
CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic...
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Domino's Pizza, Inc.
September 23, 2024 22:09 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Domino's Pizza, Inc. (DPZ) Misled Investors Regarding its Growth Projections